The $47 central target reflects a review of 12 current, attributable analyst price targets, which range from a low of $28 (Bank of America, Sell-rated) to a high of $72 (Oppenheimer). The arithmetic mean of these figures is approximately $46.50, which rounds to $47 — a level in line with widely cited aggregator averages in the $47–$49 range. This is a calculated mean, not an official published consensus.
Views differ sharply. Bullish targets cluster between $46 and $60, including H.C. Wainwright ($55, Buy), Ladenburg Thalmann ($55, initiated Buy in October 2026), Needham ($50), Mizuho ($49), Wolfe Research ($60, initiated Buy), and Piper Sandler ($46). More cautious voices include UBS ($39, Hold), Deutsche Bank ($42, Hold), Goldman Sachs ($33, Hold), and Truist ($29, Hold), while Bank of America stands alone at $28 with a Sell rating. The gap largely reflects differing assumptions about how durable WAKIX's exclusivity proves to be.
HRMY shares last traded near $32.59, leaving a required gain of roughly 44% to reach $47. That is a very large move, meaning the stock would need to not only retake but exceed its 52-week high of about $43.49.
Fundamentals are improving in parts. Third-quarter 2026 WAKIX net revenue rose to $269 million from $239 million a year earlier, with 400 net patient adds and roughly 9,350 average patients on therapy. Management reiterated full-year 2026 WAKIX revenue guidance of $1.0 billion to $1.04 billion — the first time annual sales would top $1 billion. Yet Q3 EPS of $0.81 missed the roughly $1.00 consensus, and the company announced CEO Jeffrey Dayno's retirement effective December 31, 2026, with COO Peter Anastasiou succeeding him.
The stock's 52-week range sits between roughly $25.52 and $43.49. Current levels near $32.59 place HRMY in the lower half of that range. The $43–$44 zone, anchored by the prior high, stands as the first major resistance level, followed by the psychological $50 mark. On the downside, the $25.50–$26 area has acted as durable support. A sustained move toward $47 would require clearing the prior high and confirming a breakout on volume. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Analyst price targets typically reflect a roughly 12-month research horizon, though the exact horizon varies by firm. Key items to monitor include the resolution of the AET patent litigation, any further updates on the WAKIX franchise, BP-205 clinical readouts (Phase 1 sleep-deprivation data expected in early 2027), the CEO transition, and future earnings reports that test whether the company can deliver EPS growth alongside revenue expansion. Analyst revisions following these events will matter more than the headline target itself.
The question of whether HRMY can reach $47 hinges on a calculated mean of analyst targets spanning $28 to $72 — a range that underscores genuine disagreement about the stock's future. Achieving the target would require a roughly 44% advance, a very large move that would demand both continued WAKIX growth and a favorable resolution of the patent overhang. Bullish analysts emphasize accelerating sales, a strong balance sheet, and BP-205's optionality, while bears focus on litigation risk, the Q3 earnings miss, and single-asset concentration. The balance of evidence points to a credible but by no means assured path, and investors should monitor the patent case, pipeline data, and earnings trajectory closely before drawing conclusions.
In my own analysis, I find Tickeron's AI Daily Buy/Sell Signals helpful for tracking shifts in stocks like HRMY. The tool applies AI to monitor market conditions and technical behavior, offering Buy, Sell, or Hold signals that complement fundamental research and analyst targets. It has become a regular part of how I review opportunities without replacing deeper due diligence.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Oscillator for HRMY moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 27 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRMY advanced for three days, in 206 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
HRMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HRMY as a result. In 73 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for HRMY turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 32 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for HRMY entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. HRMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.930) is normal, around the industry mean (3.596). P/E Ratio (10.578) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (2.581) is also within normal values, averaging (443.347).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders
Industry Biotechnology